血液病病人血清可溶性白细胞介素2受体的研究

STUDY ON SERUM SOLUM SOLUBLE INTERLEUKIN-2 RECEPTOR IN HAEMATOLOGY DISORDERS

用双抗体夹心酶联免疫吸附法检测了１６２例血液病病人血清可溶性白细胞介素２受体（ｓＩＬ－２Ｒ）水平。结果表明，急、慢性白血病（ＡＬ，ＣＬ）、何杰金氏淋巴瘤和骨髓增生异常综合症（ＭＤＳ）组血清ｓＩＬ－２Ｒ水平显著高于缺铁性贫血、慢性再生障碍性贫血及正常对照组（Ｐ＜０．０１）。而且血清ｓＩＬ－２Ｒ水平与病情变化有关，完全缓解（ＣＲ）的ＡＬ病人血清ｓＩＬ－２Ｒ水平较治疗前明显降低，其水平高低与维持缓解的时间有关。ＭＤＳ亚型中预后差的转化中原始细胞过多的难治性贫血病人血清ｓＩＬ－２Ｒ水平明显高于难治性贫血及难治性贫血伴环形铁粒幼红细胞者，而与急性非淋巴细胞性白血病水平无显著差异（Ｐ＞０．０５）。提示高水平的血清ｓＩＬ－２Ｒ与造血系统恶性肿瘤肿及瘤细胞负荷有密切关系，动态观察其血清ｓＩＬ－２Ｒ水平的变化有助于临床监护、疗效观察及预后估计，亦对探讨免疫功能异常与恶性血液病的发生、发展的关系有重要意义。

The serum soluble interleukin-2 reseptor(sIL-2R) level was determined in 162 patients1 with haematologic disorders by a sandwiched ELIAS method.The results showed significantly elevated levels in patients with AL,CA,HD and MDS as compared with those in patients with IDA or CAA and the normal controls.The changes were associated with the patients conditions;Patients in complete remission showed a remarkable decrease in the sIL-2R level,which was correlated with the duration of the complete remission.Patients with RAEB-T showed no clear difference from those with ANLL,We conclude that the increased serum sIL-2R level is closely related to malignant tumour in the blood-forming organs and the burden of the malignant cells,Measurement of the sIL-2R level could provide useful parameters for the observation and treatment of the disease and the evaluation of its prognosis.